Health & Fitness
Tue, February 7, 2012
TEL AVIV, Israel--([ BUSINESS WIRE ])--Compugen Ltd. ([ NASDAQ: CGEN ]) today announced that the Company will host a conference call at 10:00 AM EST on Tuesday, February 7, 2012 to review fourth quarter 2011 results. The quarterly results will be released on the Companyas website ([ www.cgen.com ]), prior to the conference call.
To access the conference call, please dial 1-888-668-9141 from the US, or +972-3-918-0609 internationally. The call will also be available via live webcast through Compugenas website, located at the following [ link ].
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-295-2634 from the US or +972-3-9255-925 internationally. The replay will be available through February 10, 2012.
About Compugen
Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology, either for Compugen or its partners. Unlike traditional high throughput trial and error experimental based drug candidate discovery, Compugenas discovery efforts are based on systematic and continuously improving in silico (by computer) product candidate prediction and selection followed by experimental validation, with selected product candidates being advanced in its Pipeline Program to the pre-IND stage. Compugenas in silico predictive models utilize a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities. The Companyas business model primarily involves collaborations covering the further development and commercialization of Compugen-discovered product candidates and various forms of adiscovery on demanda arrangements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2002, Compugen established an affiliate, Evogene Ltd. ([ www.evogene.com ]) ([ TASE: EVGN.TA ]), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at [ www.cgen.com ].
This press release may contain aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as amaya, aexpectsa, aanticipatesa, abelievesa, and aintendsa, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading aRisk Factorsa in Compugen's annual reports filed with the Securities and Exchange Commission.
